Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to -$921.6 million.

  • Dexcom's Net Cash Flow fell 2353076.92% to -$921.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $290.3 million, marking a year-over-year increase of 51504.24%. This contributed to the annual value of $290.3 million for FY2025, which is 51504.24% up from last year.
  • Latest data reveals that Dexcom reported Net Cash Flow of -$921.6 million as of Q4 2025, which was down 2353076.92% from $677.7 million recorded in Q3 2025.
  • Over the past 5 years, Dexcom's Net Cash Flow peaked at $677.7 million during Q3 2025, and registered a low of -$921.6 million during Q4 2025.
  • In the last 5 years, Dexcom's Net Cash Flow had a median value of -$12.0 million in 2023 and averaged $4.6 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 233177.97% in 2023, then crashed by 2353076.92% in 2025.
  • Quarter analysis of 5 years shows Dexcom's Net Cash Flow stood at -$391.1 million in 2021, then soared by 83.99% to -$62.6 million in 2022, then crashed by 33.23% to -$83.4 million in 2023, then skyrocketed by 95.32% to -$3.9 million in 2024, then tumbled by 23530.77% to -$921.6 million in 2025.
  • Its Net Cash Flow was -$921.6 million in Q4 2025, compared to $677.7 million in Q3 2025 and $237.7 million in Q2 2025.